摘要
目的:探析恩替卡韦联合阿德福韦酯在代偿期乙肝肝硬化治疗中的临床价值效果。方法:选取我院收治的76例代偿期乙肝肝硬化患者为研究对象,随机分两组,每组38例。给予观察组恩替卡韦联合阿德福韦酯治疗;给予对照组单纯阿德福韦酯治疗,对两组的临床治疗效果进行评价。结果:观察组患者的GGT、ALT以及PCⅢ水平变化同对照组相比(P<0.05);观察组患者的ALB水平变化低于对照组,TBA水平变化高于对照组(P<0.05)。结论:恩替卡韦联合阿德福韦酯治疗代偿期乙肝肝硬化患者,可加快患者体质恢复,值得在临床上推广和应用。
Objective： To explore the effect of entecavir combined with adefovir dipivoxil in the clinical value in the treatment of decompensated hepatitis B cirrhosis. Methods： 76 cases of hospitalized patients with cirrhosis of the liver cirrhosis were selected as the research object, randomly divided into two groups, each group of 38 cases. Given the observation group en for entecavir and adefovir dipivoxil treatment; given to the control group were treated with adefovir dipivoxil treatment, clinical therapeutic effects of two groups were evaluated. Results： the changes of GGT, ALT and PC III levels in the observation group were compared with the control group （P 〈 0.05） ; the change of ALB in the observation group was lower than that in the control group, the level of TBA was higher than that of the control group （P 〈 0.05）. Conclusion： en for entecavir and adefovir dipivoxil ester on the treatment of decompensated liver cirrhosis patients, can accelerate the constitution of the patients recovery. It is worthy of promotion and application in clinical.
